Program Description:
Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR) that is believed to exert antitumor activity by shutting down tumor cell responses to nutrients and growth factors, arresting the cell cycle in the late G1 phase, and targeting vascular endothelial growth factor (VEGF), thus inhibiting angiogenesis. Recently, small-molecule targeted inhibitors of VEGF have demonstrated antitumor activity in randomized phase III clinical trials and have been incorporated into standard disease management. This activity, sponsored by the Johns Hopkins University School of Medicine, will review efficacy results from the phase III study, as well as describe the treatment options used before the phase III everolimus study.
Activity Objectives:
After taking part in this educational activity, participants should be better able to:
- Describe treatment options as they existed before the phase III everolimus study
- Review efficacy results from the phase III study
- Evaluate the occurrence of adverse events
- Summarize the clinical course of the patient in the case study
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 1.00 |
AMA PRA Category 1 Credit(s)™
|
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. |
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. |
Faculty:
Frederic Eckhauser, M.D.
Course Director
Chairman, Department of Surgery
Johns Hopkins Hospital
Baltimore, MD
Ana M. Molina, MD
Genitourinary Service, Division of Medical Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY
Michelle Ginsberg, MD
Department of Medical Imaging
Memorial Sloan-Kettering Cancer Center
New York, NY
Suzanne Sweeney, RN
Genitourinary Service, Division of Medical Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY
Jacene Myrie
Genitourinary Service, Division of Medical Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY
Robert J. Motzer, MD
Genitourinary Service, Division of Medical Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY
Disclosures:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), The Johns Hopkins University School of Medicine has a policy of requiring the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.
The presenting faculty reported the following:
Dr Eckhauser: No relationships to disclose. Dr Molina: No relationships to disclose. Dr Ginsberg: No relationships to disclose. Ms Sweeney: No relationships to disclose. Ms Myrie: No relationships to disclose. Dr Motzer: research funding, Novartis, Pfizer, Wyeth, and GlaxoSmithKline; honorarium, Novartis.
The following article will reference unlabeled/unapproved use of drugs or products for the treatment of renal cell carcinoma.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
This program is presented by The Johns Hopkins University School of Medicine.
Instructions:
Once you are finished reading through the program, please proceed to the examination page. For the examination, you will be redirected to the Johns Hopkins University School of Medicine website to complete the posttest for this activity and receive your credits.
SYSTEM REQUIREMENTS:
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.